Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quillivant XR (methylphenidate) for ADHD in children with Down syndrome
NCT04219280Phase 4Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Oct 2020
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Cincinnati Children's Hospital Medical Center. Started Oct 2020; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04219280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04219280.